StockData
Collegium Pharmaceutical, Inc logo

Collegium Pharmaceutical, Inc (COLL) stock

COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$25.93+0.38 (+1.49%)

Close on Nov 18, 2026Market cap $844.17MP/E 20.9Yield –

Collegium Pharmaceutical free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Collegium Pharmaceutical's free cash flow for the twelve months ending Jun 30, 2026 was $328.28M, up 62.7% year over year. For fiscal 2025 it was $327.58M, up 61.1% from the year before. The highest annual figure on record is $327.58M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$327.58M+61.1%
FY2024Dec 31, 2024$203.33M-25.9%
FY2023Dec 31, 2023$274.29M+123.7%
FY2022Dec 31, 2022$122.61M+20.7%
FY2021Dec 31, 2021$101.61M+15.0%
FY2020Dec 31, 2020$88.40M+314.1%
FY2019Dec 31, 2019$21.35M-87.0%
FY2018Dec 31, 2018$163.91M–
FY2017Dec 31, 2017-$68.01M–
FY2016Dec 31, 2016-$75.53M–
FY2015Dec 31, 2015-$21.93M–
FY2014Dec 31, 2014-$17.96M–
FY2013Dec 31, 2013-$16.74M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$70.83M-2.1%
Q1 FY2026Mar 31, 2026$56.84M+4.1%
Q4 FY2025Dec 31, 2025$122.36M+45.5%
Q3 FY2025Sep 30, 2025$78.25M–
Q2 FY2025Jun 30, 2025$72.37M+7.8%
Q1 FY2025Mar 31, 2025$54.60M-11.0%
Q4 FY2024Dec 31, 2024$84.07M+14.9%
Q3 FY2024Sep 30, 2024-$9.24M-112.5%
Q2 FY2024Jun 30, 2024$67.13M-32.6%
Q1 FY2024Mar 31, 2024$61.37M+123.2%
Q4 FY2023Dec 31, 2023$73.17M+11.9%
Q3 FY2023Sep 30, 2023$73.95M+73.4%
Q2 FY2023Jun 30, 2023$99.67M+149.2%
Q1 FY2023Mar 31, 2023$27.50M–
Q4 FY2022Dec 31, 2022$65.39M+83.2%
Q3 FY2022Sep 30, 2022$42.66M+151.2%
Q2 FY2022Jun 30, 2022$39.99M+38.8%
Q1 FY2022Mar 31, 2022-$25.42M-226.2%
Q4 FY2021Dec 31, 2021$35.68M+69.1%
Q3 FY2021Sep 30, 2021$16.98M-46.6%
Q2 FY2021Jun 30, 2021$28.81M-33.0%
Q1 FY2021Mar 31, 2021$20.14M–
Q4 FY2020Dec 31, 2020$21.10M+42.9%
Q3 FY2020Sep 30, 2020$31.78M+573.5%
Q2 FY2020Jun 30, 2020$43.03M+212.9%
Q1 FY2020Mar 31, 2020-$7.51M–
Q4 FY2019Dec 31, 2019$14.77M-63.6%
Q3 FY2019Sep 30, 2019$4.72M-87.9%
Q2 FY2019Jun 30, 2019$13.75M-75.0%
Q1 FY2019Mar 31, 2019-$11.89M-140.6%
Q4 FY2018Dec 31, 2018$40.52M–
Q3 FY2018Sep 30, 2018$39.12M–
Q2 FY2018Jun 30, 2018$54.97M–
Q1 FY2018Mar 31, 2018$29.31M–
Q4 FY2017Dec 31, 2017-$13.47M–
Q3 FY2017Sep 30, 2017-$12.91M–
Q2 FY2017Jun 30, 2017-$17.92M–
Q1 FY2017Mar 31, 2017-$23.72M–
Q4 FY2016Dec 31, 2016-$23.63M–
Q3 FY2016Sep 30, 2016-$19.53M–

More Collegium Pharmaceutical figures

See a number that looks wrong?